Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7294478 | 1.00 | NFE2L2 (0.65) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL17485263 | 0.85 | NFE2L2 (0.41) | NFE2L2FBP1CYP1A2NPC1 | |
| SCHEMBL700536 | 0.80 | NFE2L2 (1.00) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL700537 | 0.80 | NFE2L2 (1.00) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL31317689 | 0.80 | NFE2L2 (1.00) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL8333086 | 0.80 | NFE2L2 (0.65) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL1431132 | 0.80 | NFE2L2 (0.65) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL1431422 | 0.80 | NFE2L2 (0.65) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL1464098 | 0.80 | NFE2L2 (0.65) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL11321270 | 0.80 | NFE2L2 (0.65) | NFE2L2PTGS1PTGS2NQO2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61291579-A | — | — | None | — | — | JP | disclosed |
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2925737-B1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN INC (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2925737-B1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| EP-2925737-A1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | Zafgen, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014071369-A1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| JP-S61291579-A | 1-(3-CINNAMYL)-4-ISOPROPYLCARBAMOYLPIPERAZINE AND PRODUCTION THEREOF | KYORIN PHARMACEUT CO LTD | 1986-12-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, ANPEP, METAP2 | NFE2L2 1990/4885PTGS1 1268/4885PTGS2 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.